Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401

Retrieved on: 2024-11-19 20:01:29

Tags for this article:

Gene delivery

Medical genetics

Molecular biology

Pervasive developmental disorders

Biotechnology

Gene therapy

Rett syndrome

Click the tags to see associated articles and topics

Neurogene Reports Serious Adverse Event in Phase 1/2 Rett Study of Gene Therapy NGN-401. View article details on hiswai:

Excerpt

In a company update, Neurogene announced that a trial participant in its phase 1 study (NCT05898620) had experienced an emerging treatment-related ...

Article found on: www.neurologylive.com

View Original Article